Format

Send to

Choose Destination
Trials. 2019 Jun 11;20(1):350. doi: 10.1186/s13063-019-3362-z.

Oleogel-S10 Phase 3 study "EASE" for epidermolysis bullosa: study design and rationale.

Author information

1
Dermatology Department, Royal Melbourne Hospital, Faculy of Medicine, Dentistry and Health Science, The University of Melbourne, Parkville, Victoria, Australia. johannes.kern@mh.org.au.
2
Department of Dermatology, Faculty of Medicine, Medical Center - University of Freiburg, Freiburg, Germany. johannes.kern@mh.org.au.
3
Department of Dermatology, University Childrens' Hospital Zurich, Zurich, Switzerland.
4
Amryt Pharmaceuticals DAC, Dublin, Ireland.
5
CSD Biostatistics Inc., Oro Valley, AZ, USA.
6
Department of Paediatric Dermatology, Great Ormond Street Hospital NHS Foundation Trust, London, UK.

Abstract

BACKGROUND:

Epidermolysis bullosa (EB) is a group of rare, genetic diseases that affect the integrity of epithelial tissues, most notably the skin. Patients experience recurrent skin wounding, with severity depending on type, sub-type, and mutation. Oleogel-S10, a formulation of birch bark extract, has demonstrated efficacy in a Phase 2 trial assessing re-epithelialization of wounds in EB. EASE (NCT03068780, EudraCT 2016-002066-32) is a randomized, Phase 3, placebo-controlled study designed to determine the efficacy of Oleogel-S10 versus placebo in patients with EB.

METHODS:

EASE is a Phase 3, two-phase study comprising a 90-day, double-blind, randomized, placebo-controlled phase, followed by 24 months of open-label, single-arm follow-up. Patients with junctional EB, dystrophic EB, or Kindler syndrome and target wounds (10 - 50cm2) present for > 21 days and < 9 months, are randomized in a 1:1 ratio to receive wound dressings according to local standard of care with or without Oleogel-S10. Placebo is based on the Oleogel-S10 vehicle, which is sunflower oil formulated to have a consistency indistinguishable from that of the active product. The primary endpoint of the trial, directed by the US health authority according to the required study endpoints for chronic cutaneous ulcer and burn wounds, is to compare the efficacy of Oleogel-S10 versus placebo according to the proportion of patients with complete closure of the target wound within 45 ± 7 days of treatment. Additional EB-focused endpoints include wound burden, patient-reported outcomes, and safety.

RESULTS:

Results of the primary endpoint are anticipated to be available by H2 2019.

TRIAL REGISTRATION:

ClinicalTrials.gov, NCT03068780 . EudraCT, 2016-002066-32. Registered on 3 March 2017.

KEYWORDS:

Betulin; Birch bark; Epidermolysis bullosa; Kindler syndrome; Oleogel; Trial design; Wound healing

PMID:
31186047
PMCID:
PMC6560757
DOI:
10.1186/s13063-019-3362-z
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center